Imaging δ- and μ-opioid receptors by PET in lung carcinoma patients

Journal of Nuclear Medicine

Volumn 48, Issue 2, 2007, Pages 207-213

  Madar, Igal ^a,b   Bencherif, Badredin ^a   Lever, John ^a   Heitmiller, Richard F ^a   Yang, Stephen C ^a   Brock, Malcolm ^a   Brahmer, Julie ^a   Ravert, Hayden ^a   Dannals, Robert ^a   Frost, James J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JHOC 4230 ^*  (United States)

Author keywords

Lung carcinoma; Opioid receptor; PET

Indexed keywords

CARFENTANIL C 11; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR ANTAGONIST; FLUORODEOXYGLUCOSE F 18; METHYLNALTRINDOLE C 11; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; TRACER; UNCLASSIFIED DRUG; COLORING AGENT; DIAGNOSTIC AGENT; NARCOTIC ANTAGONIST; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; FEMALE; HUMAN; HUMAN TISSUE; IN VIVO STUDY; INFLAMMATION; LUNG BIOPSY; LUNG CARCINOMA; LUNG PARENCHYMA; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCAR; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; STAINING; TUMOR NECROSIS; ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MIDDLE AGED; NECROSIS; PATHOLOGY; SCINTISCANNING; TISSUE DISTRIBUTION;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; COLORING AGENTS; FEMALE; HUMANS; INFLAMMATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NECROSIS; RADIOPHARMACEUTICALS; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; TISSUE DISTRIBUTION;

EID: 34047203549     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer. 2001;37(suppl 8):4-66.
2. Campa MJ, Schreiber G, Bepler G, et al. Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. Cancer Res. 1996;56:1695-1701.
3. Maneckjee R, Minna JD. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc Natl Acad Sci U S A. 1990;87:3294-3298.
4. Roth KA, Barchas JD. Small cell carcinoma cell lines contain opioid peptides and receptors. Cancer. 1986;57:769-773.
5. Schreiber G, Campa MJ, Prabhakar S, et al. Molecular characterization of the human delta opioid receptor in lung cancer. Anticancer Res. 1998;18:1787-1792.
6. Sher E, Codignola A, Passafaro M, et al. Nicotinic receptors and calcium channels in small cell lung carcinoma: functional role, modulation, and autoimmunity. Ann N Y Acad Sci. 1998;841:606-624.
7. 125I] ITIPP(psi). Nucl Med Biol. 2001;28:375-381.
8. 3H]U-69,593 to airway and pulmonary tissues of normal and sensitized rats. Peptides. 1997;18:1603-1608.
9. Frost JJ, Dannals RF, Duelfer T, et al. In vivo studies of opiate receptors. Ann Neurol. 1984;15(suppl):S85-S92.
10. 11C-carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab. 1989;9:398-409.
11. 11C-methyl)naltrindole and PET. Synapse. 1996;24:19-28.
12. Portoghese PS, Sultana M, Takemori AE. Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. J Med Chem. 1990;33:1714-1720.
13. 11C-MeNTI) : a radioligand for positron emission tomographic studies of delta opioid receptors. J Labelled Compds Radiopharm. 1995;36:137-145.
14. Bencherif B, Stumpf M, Wang G, McCaul M, Madar I, Frost J. Brain mu opioid receptor binding changes in chronic alcoholics before and after partial volume correction (PVC) [abstract]. J Nucl Med. 2001;42(suppl):107P.
15. Madar I, Bencherif B, Brandt J, Rabins PV, Zubeita JK, Frost JJ. Mu opioid receptors in Alzheimer's disease: statistical parametric mapping analysis [abstract]. J Nucl Med. 2001;42(suppl):12P.
16. Madar I, Lesser RP, Krauss G, et al. Imaging of delta- and mu-opioid receptors in temporal lobe epilepsy by positron emission tomography. Ann Neurol. 1997;41:358-367.
17. Frost JJ, Mayberg HS, Fisher RS, et al. Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol. 1988;23:231-237.
18. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF, Frost JJ. Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med. 1996;2:1225-1229.
19. 11C- carfentanil. Int J Appl Radiat Isot. 1985;36:303-306.
20. 11C-methyl)naltrindole and positron emission tomography. J Cereb Blood Flow Metab. 1999;19:956-966.
21. 11C]carfentanil: reference-tissue methods. Nucl Med Biol. 2003;30:177-186.
22. Pfeiffer A, Pasi A, Mehraein P, Herz A. Opiate receptor binding sites in human brain. Brain Res. 1982;248:87-96.
23. Zagon IS, McLaughlin PJ. Opioids and differentiation in human cancer cells. Neuropeptides. 2005;39:495-505.
24. Hatzoglou A, Kampa M, Castanas E. Opioid-somatostatin interactions in regulating cancer cell growth. Front Biosci. 2005;10:244-256.
25. Munjal I, Minna J, Maneckjee R, Bieck P, Spector S. Possible role of endogenous morphine and codeine on growth regulation of lung tissue. Life Sci. 1995;57:517-521.
26. Heusch WL, Maneckjee R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis. 1998;19:551-556.
27. Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 1994;5:1033-1040.
28. Gomez-Flores R, Caballero-Hernandez D, Tamez-Guerra R, et al. Increased survival of tumor-bearing mice by the delta opioid SNC 80. Anticancer Res. 2005;25:4563-4567.
29. Hatsukari I, Hitosugi N, Matsumoto I, Nagasaka H, Sakagami H. Induction of early apoptosis marker by morphine in human lung and breast carcinoma cell lines. Anticancer Res. 2003;23:2413-2417.
30. Jaglowski JR, Zagon IS, Stack BC Jr. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2005;56:97-104.
31. Smith JP, Conter RL, Bingaman SI. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs. 2004;15:203-209.
32. McLaughlin PJ, Zagon IS. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor. Int J Oncol. 2006;28:1577-1583.
33. Fichna J, Janecka A. Opioid peptides in cancer. Cancer Metastasis Rev. 2004;23:351-366.
34. Entschladen F, Bastian P, Niggemann B, Zaenker KS, Lang K. Inhibition of cell migration via G protein-coupled receptors to opioid peptides and angiotensin. Ann N Y Acad Sci. 2004;1028:320-328.
35. Harimaya Y, Koizumi K, Andoh T, Nojima H, Kuraishi Y, Saiki I. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett. 2002;187:121-127.